Biotech | May 01, 2022
BeiGene to open new site at Princeton, New Jersey
Flagship U.S. facility will include biologic manufacturing and late stage research and clinical development of innovative cancer medicines
Flagship U.S. facility will include biologic manufacturing and late stage research and clinical development of innovative cancer medicines
The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
Submission to regulators globally is based on phase 2/3 studies of mRNA-1273 in young children
Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo
First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
Diana is a senior leader with more than 38 years of field experience in U.S. FDA’s Office of Regulatory Affairs (ORA)
Star Array's focus has been on the development of an automated (cassette-based) nucleic acid purification system coupled with its superfast nucleic acid amplification technology
Biocon Biologics’ Insugen formulations will be available to patients at all Ministry of Health hospitals, district health offices and health clinics
Subscribe To Our Newsletter & Stay Updated
